Cargando…

Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study

BACKGROUND: Negative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demjaha, Arsime, Galderisi, Silvana, Glenthøj, Birthe, Arango, Celso, Mucci, Armida, Lawrence, Andrew, O'Daly, Owen, Kempton, Matthew, Ciufolini, Simone, Baandrup, Lone, Ebdrup, Bjørn H., Rodriguez-Jimenez, Roberto, Diaz-Marsa, Maria, Díaz-Caneja, Covadonga Martinez, Winter van Rossum, Inge, Kahn, Rene, Dazzan, Paola, McGuire, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277764/ https://www.ncbi.nlm.nih.gov/pubmed/35197142 http://dx.doi.org/10.1017/S0033291722000010

Ejemplares similares

Scalability of the Positive and Negative Syndrome Scale in first‐episode schizophrenia assessed by Rasch models
por: Baandrup, Lone, et al.
Publicado: (2022)

Prediction of drop-out and functional impairment in recent-onset schizophrenia spectrum disorders
por: Mucci, A., et al.
Publicado: (2021)

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
por: Worker, Amanda, et al.
Publicado: (2023)

Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis
por: Fraguas, David, et al.
Publicado: (2017)

Socioeconomic status and severe mental disorders: a bidirectional multivariable Mendelian randomisation study
por: Andreu-Bernabeu, Álvaro, et al.
Publicado: (2023)

T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISODE SCHIZOPHRENIA
por: Pina-Camacho, Laura, et al.
Publicado: (2020)

Cognitive-enhancing effects of aripiprazole: a case report
por: Mucci, Armida, et al.
Publicado: (2008)

31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS
por: Dazzan, Paola, et al.
Publicado: (2018)

The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies
por: Harari, Julia H., et al.
Publicado: (2017)

T24. CHANGES IN TELOMERE LENGTH IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTHS FOLLOW-UP STUDY
por: Ayora, Mirian, et al.
Publicado: (2020)

Predictors of outcome in early-onset psychosis: a systematic review
por: Díaz-Caneja, Covadonga M, et al.
Publicado: (2015)

F19. TELOMERE SHORTENING IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTH FOLLOW-UP STUDY
por: Fraguas, David, et al.
Publicado: (2018)

S80. CHILDHOOD TRAUMA AND SOCIAL COGNITION IN DELUSIONAL PSYCHOSES
por: Díaz-Caneja, Covadonga, et al.
Publicado: (2020)

Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
por: Pandit, R., et al.
Publicado: (2019)

Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial
por: Baandrup, Lone, et al.
Publicado: (2016)

White matter microstructure and sleep-wake disturbances in individuals at ultra-high risk of psychosis
por: Rasmussen, Jesper Ø., et al.
Publicado: (2022)

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
por: Rasmussen, Jesper Østrup, et al.
Publicado: (2021)

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
por: Vita, Antonio, et al.
Publicado: (2022)

Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review
por: Giordano, Giulia Maria, et al.
Publicado: (2021)

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
por: Ishøy, Pelle L, et al.
Publicado: (2014)

Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: case series
por: Demjaha, Arsime, et al.
Publicado: (2022)

Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
por: Galderisi, Silvana, et al.
Publicado: (2021)

Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
por: Collo, Ginetta, et al.
Publicado: (2020)

Corrigendum: Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
por: Collo, Ginetta, et al.
Publicado: (2021)

T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT
por: Santonja, Javier, et al.
Publicado: (2020)

Gender Differences in Neuropsychological Performance across Psychotic Disorders – a Multi-Centre Population Based Case-Control Study
por: Zanelli, Jolanta, et al.
Publicado: (2013)

SoCIAL – training cognition in schizophrenia: a pilot study
por: Palumbo, Davide, et al.
Publicado: (2017)

Efficacy of a Web-Enabled, School-Based, Preventative Intervention to Reduce Bullying and Improve Mental Health in Children and Adolescents: Study Protocol for a Cluster Randomized Controlled Trial
por: Díaz-Caneja, Covadonga M., et al.
Publicado: (2021)

Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders
por: de Haan, Lieuwe, et al.
Publicado: (2023)

Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
por: Susai, Subash Raj, et al.
Publicado: (2023)

Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature
por: Giordano, Giulia M., et al.
Publicado: (2022)

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
por: Baltzersen, Olga B., et al.
Publicado: (2020)

Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features
por: Stanghellini, Giovanni, et al.
Publicado: (2020)

Unveiling the Associations between EEG Indices and Cognitive Deficits in Schizophrenia-Spectrum Disorders: A Systematic Review
por: Perrottelli, Andrea, et al.
Publicado: (2022)

The Brief negative Symptom Scale (BNSS): a systematic review of measurement properties
por: Weigel, Lucia, et al.
Publicado: (2023)

Optimized Brain Extraction for Pathological Brains (optiBET)
por: Lutkenhoff, Evan S., et al.
Publicado: (2014)

OptiPrep Density Gradient Solutions for Nonmammalian Organelles
por: Graham, John M.
Publicado: (2002)

OptiPrep™ Density Gradient Solutions for Mammalian Organelles
por: Graham, John
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_gub9ccnv4ld0p5kji1vjq26oob